Infectious disease
In an interview this morning with CNN, Dr. Anthony Fauci said the government will help finance Phase III studies of three vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
With more than 130 COVID-19 vaccines in development around the world, many of them are bound to fail. When they do, will that erode the public trust in the vaccines that are approved? The answer largely depends on where in the development cycle the vaccines fail and the scope of their failure.
Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.
The annual Biotechnology Innovation Organization meeting kicked off Monday with the proverbial passing of the baton from longtime head Jim Greenwood to Michelle McMurry-Heath, who was tapped to take over the organization last month.
A small study that examined the use of famotidine in a group of 10 patients with COVID-19 suggests that the drug could potentially ease the symptoms of the condition.
Poll after poll shows that many Americans – 30% to 50% – are unwilling to be vaccinated against COVID-19 once a vaccine becomes available. Meanwhile, officials are banking on widespread vaccination to allow society to return to normal, without masks or social distancing.
Researchers with The U.S. Oncology Network discovered AstraZeneca’s Calquence (acalabrutinib) benefited a small number of patients who have severe infections of the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
PRESS RELEASES